A Retrospective Evaluation of Ototoxicity Monitoring in a Cohort of Pediatric Patients With Solid Tumors, Treated in the Dutch National Cancer Center

Publication date

2024-11

Authors

Diepstraten, Franciscus A
Bertram, Odette M M
Helleman, Hiske W
Boerboom, Ralf A
van Grotel, Martine
Zsíros, József
Tytgat, Godelieve A M
van Tinteren, Harm
Stokroos, Robert JORCID 0000-0001-8037-2573ISNI 0000000392507919
Janssens, Geert O.ORCID 0000-0002-0331-713X

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

cc_by

Abstract

INTRODUCTION: Ototoxicity is an adverse effect of childhood cancer treatment with a negative impact on speech-language development and quality of life. This study aimed to retrospectively assess ototoxicity monitoring in a national cohort of pediatric patients with solid tumors, examining the frequency and determinants associated with hearing loss (HL). METHODS: This retrospective cohort study included 305 patients treated between 2015 and 2020 at the Princess Máxima Center. Patients receiving platinum agents, head and neck radiotherapy, and/or ear-nose-throat surgery were analyzed. Electronic patient files provided demographic, clinical, and audiological data. HL was defined as Muenster ≥ 2b or SIOP ≥ 2 grade. Associations between clinical characteristics and HL occurrence were analyzed using logistic regression analysis. RESULTS: Audiological monitoring was performed at baseline (62.6%), during treatment (79.0%), and at the end of treatment (82.1%). Post treatment, 51.2% and 36.5% experienced Muenster and SIOP-defined HL, respectively. Multivariable analyses revealed that age at diagnosis (OR 0.9, 95% CI 0.9-1.0), total cumulative dose cisplatin per 100 mg/m 2 (OR 1.6, 95% CI 1.4-2.0), and vincristine treatment (OR 3.3, 95% CI 1.4-7.8) remained significantly associated with Muenster grade ≥ 2b HL. Age at diagnosis in years (OR 0.9, 95% CI 0.8-1.0), total cumulative dose cisplatin per 100 mg/m 2 (OR 1.5, 95% CI 1.2-1.8), and male sex (OR 2.7, 95% CI 1.4-5.3) were associated with SIOP ≥ 2 HL. CONCLUSION: This study shows that more than half of the children treated with ototoxic cancer therapies develop HL by the end of treatment. Therefore, audiological monitoring during and after treatment is essential. Improved insight into clinical determinants aids in identifying patients at high risk for HL, who may benefit from prevention strategies that are currently being implemented.

Keywords

Adolescent, Antineoplastic Agents/adverse effects, Child, Child, Preschool, Cisplatin/adverse effects, Female, Hearing Loss/chemically induced, Humans, Infant, Male, Neoplasms/drug therapy, Netherlands/epidemiology, Ototoxicity/etiology, Quality of Life, Retrospective Studies, Risk Factors, Journal Article

Citation

Diepstraten, F A, Bertram, O M M, Helleman, H W, Boerboom, R A, van Grotel, M, Zsíros, J, Tytgat, G A M, van Tinteren, H, Stokroos, R J, Janssens, G O, Hoetink, A E, van den Heuvel-Eibrink, M M & Meijer, A J M 2024, 'A Retrospective Evaluation of Ototoxicity Monitoring in a Cohort of Pediatric Patients With Solid Tumors, Treated in the Dutch National Cancer Center', Cancer reports (Hoboken, N.J.), vol. 7, no. 11, e70046. https://doi.org/10.1002/cnr2.70046